COMMUNIQUÉS West-GlobeNewswire

Sana Biotechnology to Present at the TD Cowen Immunology & Inflammation Summit
04/11/2025
SEATTLE, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation [...]
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
04/11/2025
- New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators – - Conference call scheduled for Wednesday, November 12, 2025, at [...]
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
04/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing [...]
InnovAge Announces Financial Results for the Fiscal First Quarter Ended September 30, 2025
04/11/2025
DENVER, Nov. 04, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible [...]
Amwell® Announces Results for Third Quarter 2025
04/11/2025
BOSTON , Nov. 04, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results for the third [...]
Revolution Medicines to Participate in November 2025 Investor Conferences
04/11/2025
REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
04/11/2025
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and [...]
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/11/2025
MONTREAL and CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a [...]
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
04/11/2025
Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, oral small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA [...]
Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update
04/11/2025
On track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease [...]
Prenetics Announces Third Quarter 2025 Financial Results Release Date and Inaugural Earnings Conference Call
04/11/2025
CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced it will release financial results for the [...]
Solana Company Files Application to Cease to Be a Reporting Issuer in Canada
04/11/2025
NEWTOWN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (“ Solana ” or the “ Company ”) today announced that it has applied to the British Columbia Securities Commission, as principal regulator, [...]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/11/2025
CHARLESTOWN, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
Édition 2025 du congrès mondial du collectif médical polonais « Save a Life » : une mission d’envergure mondiale répondant à l’objectif de faire progresser l’expertise en sauvetage de vies
04/11/2025
Un rassemblement des professionnels de santé polonais répartis à travers le monde placé sous le signe de la coopération internationale et de l’excellence médicale VARSOVIE, Pologne, 04 nov. 2025 (GLOBE NEWSWIRE) -- Du [...]
Fueling Discovery: Misophonia Research Fund Launches New Team Science Award, Expands 2026 Funding Opportunities, and Announces Latest Grantee Cohort
04/11/2025
CHICAGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The Misophonia Research Fund (MRF), an initiative of the REAM Foundation, announces a major expansion of its support of misophonia research – launching the first-ever team [...]
Chemed Corporation to Present at the UBS 2025 Global Healthcare Conference
04/11/2025
CINCINNATI, Ohio, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the UBS 2025 Global Healthcare Conference on Tuesday, November 11, 2025, at [...]
Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
04/11/2025
– Mean weight loss of 19.2% I at 6 mg with no plateau and favorable safety profile in 48-week Phase 3 clinical trial – – Data builds on previously reported Phase 2 results that showed mean weight loss of 23.6% I at 8 mg [...]
Omada Health to Present Real-World Evidence at ObesityWeek 2025 Demonstrating Enhanced Outcomes for Current and Former GLP-1 Users
04/11/2025
Results suggest sustained, long-term impact of Omada’s program on weight loss and longer medication persistence SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit [...]
Rivus Pharmaceuticals Presents Preclinical Data for Controlled Metabolic Accelerator (CMA) Pipeline Showing Fat-Selective, Muscle-Preserving Weight Loss in Obesity at ObesityWeek®
04/11/2025
First data from Rivus’ preclinical CMA pipeline showing potential as monotherapy and in combination with GLP-1s CHARLOTTESVILLE, Va. and SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Rivus [...]

Pages